{
    "nctId": "NCT06636591",
    "briefTitle": "Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer",
    "officialTitle": "A Prospective, Open-label, Single-center, Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer Female, HER2-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Assessment of immune activating response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female\uff0cage 18-70 years.\n2. Histologically confirmed invasive cancer of the breast, and patients meeting cT2-4N+M0 criteria;\n3. TNBC non-immunoregulation subtype or HR+/HER2- status were measured by immunohistochemistry (IHC);\n4. At least one measurable lesion according to RECIST 1.1 criteria;\n5. Normal organ and marrow function: Hemoglobin (HB) \u226590 g/L (No blood was transfused within 14 days), Absolute neutrophil count \u2265 1500/\u03bcL, Platelets \u2265 75,000/\u03bcL, Total bilirubin \u2264 1.5 x ULN), aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT) \u2264 3 x ULN, creatinine \\< 1 x ULN, endogenous creatinine clearance \\> 50 ml/min (Cockcroft-Gault formula);\n6. LVEF \u226555%;\n7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n8. Non-pregnant and non-lactating, fertile female subjects were required to use a medically approved contraceptive method for the duration of the study treatment and at least 3 months after the last use of the study drug;\n9. Ability to understand and willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n1. Previous cytotoxic chemotherapy, endocrine therapy, biological therapy or radiotherapy for any reason;\n2. Patients with New York Heart Association (NYHA) grade II or above heart disease (including grade II);\n3. Patients with severe systemic infections or other serious diseases;\n4. Patients with known allergy or intolerance to the study drug or its excipients;\n5. Other malignant tumors in the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer;\n6. Pregnant or lactating patients of childbearing age who refused to take appropriate contraceptive measures during the course of the study;\n7. Participated in other trial studies within 30 days before the administration of the first dose of the study drug;\n8. Endocrine system disorders;\n9. Patients who were judged by the investigator to be unsuitable for this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}